iShares Biotechnology ETF (NASDAQ:IBB) to Issue Dividend of $0.13

iShares Biotechnology ETF (NASDAQ:IBBGet Free Report) announced a dividend on Wednesday, March 20th, NASDAQ reports. Stockholders of record on Friday, March 22nd will be given a dividend of 0.126 per share by the financial services provider on Wednesday, March 27th. The ex-dividend date is Thursday, March 21st.

iShares Biotechnology ETF Price Performance

IBB traded up $0.74 during trading on Thursday, reaching $137.23. 1,635,342 shares of the stock were exchanged, compared to its average volume of 1,909,515. The stock’s 50 day moving average price is $136.40 and its two-hundred day moving average price is $128.45. iShares Biotechnology ETF has a twelve month low of $111.83 and a twelve month high of $141.16.

Institutional Investors Weigh In On iShares Biotechnology ETF

Several hedge funds have recently bought and sold shares of the company. Moneta Group Investment Advisors LLC boosted its position in iShares Biotechnology ETF by 131,598.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,469,845 shares of the financial services provider’s stock worth $586,846,000 after purchasing an additional 4,466,451 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of iShares Biotechnology ETF by 159.9% during the 1st quarter. JPMorgan Chase & Co. now owns 1,966,359 shares of the financial services provider’s stock worth $253,975,000 after buying an additional 1,209,700 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of iShares Biotechnology ETF by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock worth $204,332,000 after buying an additional 521,820 shares during the period. Jane Street Group LLC grew its stake in iShares Biotechnology ETF by 5.4% in the 4th quarter. Jane Street Group LLC now owns 1,002,554 shares of the financial services provider’s stock valued at $131,625,000 after buying an additional 50,999 shares during the last quarter. Finally, First Republic Investment Management Inc. raised its holdings in iShares Biotechnology ETF by 2.8% in the 2nd quarter. First Republic Investment Management Inc. now owns 222,322 shares of the financial services provider’s stock valued at $26,152,000 after acquiring an additional 6,129 shares during the period. 69.61% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Company Profile

(Get Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Stories

Dividend History for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.